Core Viewpoint - Zhaoli Pharmaceutical has established a joint research center with Zhejiang University to enhance its "One Road to C" strategy, focusing on AI-driven development of health products based on the Wuling mushroom [1] Group 1: Partnership and Strategic Development - The collaboration aims to create a food and drug knowledge graph and develop AI models to empower functional food formulation [1] - Zhaoli Pharmaceutical will leverage cutting-edge technology from Zhejiang University to explore the health benefits of Wuling mushroom and transform them into innovative health products [1] - This partnership is part of the company's broader strategy to deepen the integration of industry, academia, and research [1] Group 2: Market and Financial Performance - In the first half of the year, Zhaoli Pharmaceutical expects a net profit attributable to shareholders of 36.8 million to 38.8 million yuan, representing a year-on-year increase of 24.30% to 31.06% [1] - The company has seen growth in sales across its core products and traditional Chinese medicine formula granules [1] - The strategic upgrade is expected to enhance the company's technological moat, enrich its product matrix, and expand its consumer market [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a revenue growth of approximately 12% year-on-year in the first half of 2025, with a projected net profit attributable to shareholders ranging from 368 to 388 million yuan, reflecting a year-on-year increase of 24.3% to 31.06% [7] - The core products are showing steady growth, with significant results from the expansion of the OTC (over-the-counter) channels, which is expected to enhance the company's profitability [7] - The strategic layout of "Wuling Fungus+" is anticipated to open a second growth curve in the medium term, with plans to invest 20 million yuan in developing unique products related to Wuling Fungus [7] Financial Forecasts - The company’s total revenue is projected to reach 3,178 million yuan in 2025, with a year-on-year growth of 23.29% [1] - The net profit attributable to shareholders is forecasted to be 655.34 million yuan in 2025, representing a year-on-year increase of 29.06% [1] - The earnings per share (EPS) is expected to be 0.93 yuan in 2025, with a price-to-earnings (P/E) ratio of 20.26 based on the current price [1]

Group 1 - The core viewpoint of the news is that Zhaoli Pharmaceutical has signed a cooperation agreement with Zhejiang University to establish a joint research center focused on the integration of artificial intelligence in the development of health products based on the unique properties of the Wuling fungus [1][2] - The collaboration aims to create a knowledge graph for food and medicine, develop AI-driven models and intelligent agents for functional food formulation, and assist in the long-term technological development strategy of the company [1][2] - Zhaoli Pharmaceutical's strategy "一路向C" focuses on expanding into the consumer market, leveraging market opportunities arising from external policies and the aging population, while enhancing its product offerings and brand recognition [2] Group 2 - The company anticipates a strong financial performance, projecting a net profit of 36.8 million to 38.8 million yuan for the first half of the year, representing a year-on-year growth of 24.30% to 31.06% [3] - The sales revenue for the company increased by approximately 12% compared to the previous year, driven by core products such as Wuling capsules and Lingze tablets, which continue to show strong market growth [3] - The establishment of the research center is expected to enhance the company's technological capabilities, enrich its product matrix, and cultivate new profit growth points, thereby supporting sustainable development [2][3]

Group 1 - A total of 18 companies listed on the ChiNext board have released their performance forecasts for the first half of the year, with 13 companies expecting profit increases, 1 company expecting to turn a profit, 1 company expecting a profit decrease, and 1 company expecting a loss [1][3] Group 2 - The performance forecast details include various companies with significant expected profit growth, such as: - Hanyu Pharmaceutical (300199) with a projected profit increase of 1567.36% [2] - Chuanjin Nuo (300505) with a projected profit increase of 167.27% [2] - Chenguang Biotech (300138) with a projected profit increase of 117.36% [2] - Huizhong (300371) with a projected profit increase of 100.00% [2] - Taotao Automotive (301345) with a projected profit increase of 84.08% [2] Group 3 - Companies with performance forecasts indicating a decrease or loss include: - Zairun (301636) with a projected profit decrease of 5.43% [2] - Yuyou Green Energy (301590) with a projected profit decrease of 6.57% [2] - Juguang (300203) with a projected loss of 205.37% [2]

Group 1: Company Performance - Northern Rare Earth expects a net profit of 900 million to 960 million yuan for the first half of 2025, representing a year-on-year increase of 1882.54% to 2014.71% [1] - Muyuan Foods anticipates a net profit of 10.5 billion to 11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 924.6% to 973.39% [2] - Hongta Securities projects a net profit of 651 million to 696 million yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [3] Group 2: Business Developments - Dazhihui clarifies that it has not engaged in businesses related to "stablecoins," "virtual asset trading," or "cross-border payments," following a significant stock price fluctuation [4] - Bluetech announces a share transfer agreement where its actual controller will change, with the Ma'anshan Municipal Government becoming the actual controller after the transfer of 18% of shares [5] Group 3: Industry Trends - Jiangsu Electric Power reports a 5.01% year-on-year increase in electricity generation for the first half of 2025 [6] - Jin'an Guoji anticipates a non-recurring net profit growth of 4700% to 6300% for the first half of 2025 [6] - New Beiyang expects a non-recurring net profit growth of 650% to 720% for the first half of 2025 [6]

问题四：在 C 端无论是 OTC 还是消费品都面临着各种竞争，公 司如何建立自己的核心竞争力？ 证券代码：300181 证券简称：佐力药业 编号：2025-011 浙江佐力药业股份有限公司 投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | ☑媒体采访 □业绩说明会 | | | ☑新闻发布会 □路演活动 | | | □现场参观 | | | 其他 | | 参与单位名称及 | 长城证券；开源证券；长江证券；申万宏源；远信投资；永安 | | 人员姓名（以上 | 国富；信达证券；长信基金；富国基金；金百镕；兴业证券； | | | 兴业基金；海富通基金；深圳新思哲；广发资管；平安证券； | | 排名不分先后） | 华福证券；诺德基金；东吴证券；信诚基金；歌汝私募基金； | | | 光大证券；衡锐资本；东方证券；瓦琉咨询；方正证券；信达 | | | 澳亚基金；招商证券；蓝林科技；东财医药；山西恒天成；玖 | | | 龙资管；中邮证券；太平资产；金斧子资本；东海证券；中信 | | | 证券；浙商证券；华创证券；华泰证券；华泰柏瑞；华西证券； | | | ...

佐力药业（300181）公告，公司与浙江大学签署了《浙江大学-佐力药业智赋食药联合研发中心共建协 议》和《技术开发(委托)合同》，计划投入金额共计2000万元。其中，共建协议涉及1000万元，合同涉 及1000万元。合作旨在利用AI技术研发食药同源垂类大模型与智能体，赋能乌灵菌功能食品/日化用品 等配方和工艺。此次合作有利于强化公司技术护城河，丰富产品矩阵，拓宽C端市场空间，提升产品竞 争力，为公司大健康产业发展注入科技驱动力。 ...

佐力药业（300181）公告，预计2025年上半年净利润为3.68亿元-3.88亿元，比上年同期的2.96亿元增长 24.30%-31.06%。 ...

关于与浙江大学签署联合研发中心共建协议 及技术开发（委托）合同的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"或者"佐力药业"）近日与 浙江大学经友好协商，本着"互惠互利、优势互补、合作创新、共同发展"的原 则，共同签署了《浙江大学-佐力药业智赋食药联合研发中心共建协议》（以下 简称"共建协议"）和《技术开发（委托）合同》（以下简称"合同"），公司 计划投入上述两项协议金额共计 2000 万元人民币。 公司一直秉承"辅佐人类身体健康，致力祖国医药发展"的战略使命，围绕 乌灵菌专注开发乌灵系列相关产品，同时也积极关注乌灵菌大健康产品领域的研 发。公司此次与浙江大学的联合共建项目是产学研深度融合、科技赋能产业的战 略抉择。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等有关规定， 上述事项不涉及关联交易，亦不构成《上市公司重大资产重组管理办法》规定的 重大资产重组，无需提交公司董事会、股东大会审议批准。现将有关事项公告如 下： 一 ...

浙江佐力药业股份有限公司 监事会关于 2024 年限制性股票激励计划预留授予 激励对象名单（截至预留授予日）的核查意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》(以下简称"《证券法》")、《深圳证券交易所创业板股票上市 规则》（以下简称"《上市规则》"）《上市公司股权激励管理办法》（以下简 称"《管理办法》"）等法律、法规及《公司章程》的规定，浙江佐力药业股份 有限公司（以下简称"公司"）监事会对公司 2024 年限制性股票激励计划（以 下简称"本次激励计划"）预留授予激励对象名单（截至预留授予日）进行核查， 现发表如下意见： 一、本次获授限制性股票的激励对象均不存在《管理办法》《上市规则》规 定的不得成为激励对象的情形： （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证 ...